Bernstein Adjusts BeiGene's Price Target to $161 From $196, Maintains Market Perform Rating
BeiGene Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE) and BeiGene (BGNE)
BeiGene: Hold Recommendation Amidst Mixed Financial Indicators and Robust Drug Pipeline Growth
UBS Cuts BeiGene Stock Target to $285.70, Maintains Buy Rating
Analysts Are Bullish on These Healthcare Stocks: Athira Pharma (ATHA), BeiGene (BGNE)
BeiGene Analyst Ratings
BeiGene Hold Rating Upheld Amid Revenue Growth and Market Challenges
BeiGene: Balancing Robust Zanubrutinib Sales and Financial Challenges – A Hold Rating
Brukinsa's Market Dominance and BeiGene's Promising Pipeline Fuel Buy Rating and New Price Target
Analysts Are Bullish on Top Healthcare Stocks: BeiGene (BGNE), McKesson (MCK)
BeiGene Hold Rating Maintained Amid Mixed Drug Sales and Revised Financial Risk Profile
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), BeiGene (BGNE) and Catalent (CTLT)
BeiGene Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: BeiGene (BGNE), Travere Therapeutics (TVTX)
BeiGene's Hold Rating: Balancing BGB-16673's Promise With Market Realities
Leerink Partners Sticks to Its Buy Rating for BeiGene (BGNE)
BeiGene Holds Steady: A Balanced View Amidst Growth and Market Uncertainty
BeiGene's Promising Pipeline and Buy Rating Endorsed by Analyst Jill Wu
Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and BeiGene (BGNE)
No Data